Anna Svatikova1, Stephen L Kopecky2. 1. Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. 2. Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. kopecky.stephen@mayo.edu.
Abstract
PURPOSE OF REVIEW: Cholesterol management in the current era is discussed. Aggressive reduction of low density lipoprotein (LDL) cholesterol plays a key role in primary and secondary prevention of heart disease. Statins are the recommended first-line therapy in patients with hyperlipidemia; however, additional complementary approaches are frequently needed for patients who fail to reach their target LDL. RECENT FINDINGS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs that provide dramatic lowering of LDL and promise outcome benefit. Despite great enthusiasm about their cardiovascular benefit, concerns have been raised regarding their cost and added value to the healthcare system. Although cost-effectiveness studies have yielded inconclusive results, analyses suggest that the current cost of PCSK9 inhibitors is disproportionately high and must be significantly reduced to add positive net benefit to healthcare system. PCSK9 inhibitors significantly lower LDL cholesterol. Further outcome data and cost-effectiveness analyses are needed to overcome the current barriers with PCSK9 inhibitors that patients, physicians, and payers face.
PURPOSE OF REVIEW: Cholesterol management in the current era is discussed. Aggressive reduction of low density lipoprotein (LDL) cholesterol plays a key role in primary and secondary prevention of heart disease. Statins are the recommended first-line therapy in patients with hyperlipidemia; however, additional complementary approaches are frequently needed for patients who fail to reach their target LDL. RECENT FINDINGS:Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs that provide dramatic lowering of LDL and promise outcome benefit. Despite great enthusiasm about their cardiovascular benefit, concerns have been raised regarding their cost and added value to the healthcare system. Although cost-effectiveness studies have yielded inconclusive results, analyses suggest that the current cost of PCSK9 inhibitors is disproportionately high and must be significantly reduced to add positive net benefit to healthcare system. PCSK9 inhibitors significantly lower LDL cholesterol. Further outcome data and cost-effectiveness analyses are needed to overcome the current barriers with PCSK9 inhibitors that patients, physicians, and payers face.
Authors: Maciej Banach; Manfredi Rizzo; Peter P Toth; Michel Farnier; Michael H Davidson; Khalid Al-Rasadi; Wilbert S Aronow; Vasilis Athyros; Dragan M Djuric; Marat V Ezhov; Robert S Greenfield; G Kees Hovingh; Karam Kostner; Corina Serban; Daniel Lighezan; Zlatko Fras; Patrick M Moriarty; Paul Muntner; Assen Goudev; Richard Ceska; Stephen J Nicholls; Marlena Broncel; Dragana Nikolic; Daniel Pella; Raman Puri; Jacek Rysz; Nathan D Wong; Laszlo Bajnok; Steven R Jones; Kausik K Ray; Dimitri P Mikhailidis Journal: Expert Opin Drug Saf Date: 2015-04-24 Impact factor: 4.250
Authors: Stephen Devries; Arthur Agatston; Monica Aggarwal; Karen E Aspry; Caldwell B Esselstyn; Penny Kris-Etherton; Michael Miller; James H O'Keefe; Emilio Ros; Anne K Rzeszut; Beth A White; Kim A Williams; Andrew M Freeman Journal: Am J Med Date: 2017-05-25 Impact factor: 4.965
Authors: Jeffrey L Anderson; Paul A Heidenreich; Paul G Barnett; Mark A Creager; Gregg C Fonarow; Raymond J Gibbons; Jonathan L Halperin; Mark A Hlatky; Alice K Jacobs; Daniel B Mark; Frederick A Masoudi; Eric D Peterson; Leslee J Shaw Journal: J Am Coll Cardiol Date: 2014-03-27 Impact factor: 24.094
Authors: Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown Journal: J Clin Lipidol Date: 2014-07-15 Impact factor: 4.766
Authors: Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano Journal: Atherosclerosis Date: 2016-09-01 Impact factor: 5.162
Authors: Michael J Koren; Robert P Giugliano; Frederick J Raal; David Sullivan; Michael Bolognese; Gisle Langslet; Fernando Civeira; Ransi Somaratne; Patric Nelson; Thomas Liu; Rob Scott; Scott M Wasserman; Marc S Sabatine Journal: Circulation Date: 2013-11-19 Impact factor: 29.690
Authors: Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo Journal: JAMA Date: 2016-08-16 Impact factor: 56.272
Authors: Kenny Mendoza-Herrera; Andrea Pedroza-Tobías; César Hernández-Alcaraz; Leticia Ávila-Burgos; Carlos A Aguilar-Salinas; Simón Barquera Journal: Int J Environ Res Public Health Date: 2019-10-22 Impact factor: 3.390